GSK regulatory milestones show why London cannabis attention remains selective

GSK regulatory milestones show why London cannabis attention remains selective →

Highlights GSK reported meaningful regulatory progress in infectious disease and oncology during an otherwise quiet London session. No comparable same-day catalyst emerged from a current UK-listed cannabis company. The contrast reflects dif…